Hakim M.
- Country
- France
- Department
- Oncologie médicale
Research Overview
- Phase I Study of XL092 Monotherapy and Combination Therapy in Advanced Solid Tumors: ccRCC, nccRCC, HR+ BC, mCRPC, and CRC
- Phase Ib/II Study of AMO959 with Lutetium (177Lu) Vipivotide Tetraxetan and Combination Therapy in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- A Phase 3 Study of JNJ-78278343 and Docetaxel Versus Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 390 of 665 partner sites.
Specializations
Urological Oncology
The investigator specializes in advanced treatment approaches for muscle-invasive bladder cancer and urothelial carcinoma, with particular focus on innovative therapeutic strategies.
- Bladder Cancer Management
- Locally Advanced Urothelial Cancer
- High-Risk Invasive Disease
Expertise extends to perioperative treatment protocols and immunotherapy applications in bladder cancer care.
Prostate Cancer Research
Demonstrates extensive involvement in treating metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
- Novel Hormonal Therapies
- Radiopharmaceutical Treatment
- Advanced Stage Disease Management
Focus includes targeted therapies and combination treatment approaches for advanced prostate cancer.
Kidney Cancer Treatment
Specializes in treating metastatic renal cell carcinoma, including cases with brain metastases and both clear cell and non-clear cell variants.
- Immunotherapy Combinations
- Targeted Molecular Therapies
- Brain Metastasis Management
Expertise in implementing novel therapeutic strategies for complex renal cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.